drugset / Trial / NCT02665754

Intralymphatic Immunotherapy for House Dust Mite, Dog, and Cat Allergy Using Tyrosine S® in Allergic Rhinitis

NCT02665754

RandomizedParallel-groupQuadruple-blindTreatment

Summary

The investigators will perform double-blinded placebo-controlled randomized clinical trial which evaluates the efficacy and safety of allergen-specific intralymphatic immunotherapy (ILIT) for allergens including Dermatophagoides farinae (Df), Dermatophagoides pteronyssinus (Dp), cat, and dog that are sensitized and provoke rhinitis-related symptoms in patients with allergic rhinitis (AR), using allergen extracts for allergen-specific immunotherapy (Tyrosine S, Allergy Therapeutic, West Sussex, UK).

Timeline

Start
2016-07
Primary completion
2019-12
Completion
2020-01

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Allergen extract Unknown 0.5 ml Other
Background Cetirizine Other / unclassified Oral
Background Ciclesonide Other / unclassified Intranasal

Indications